Studies have demonstrated that use of CGM by T2D patients confers significant reductions in HbA1c levels,10,13–15,17,24,67,68 significant increases in percent time in range (defined as glucose values between 70 and 180 mg/dL, %TIR),10,17 significant decreases in percent time below range (defined as glucose values <70 mg/dL, %TBR),21,22 and significant reductions in diabetes-related hospitalizations31,69 regardless of insulin regimen. The gene discussed is INS; the disease is diabetes mellitus.